Takeaway
- For pediatric patients with COVID-19 who develop a rare Kawasaki-like syndrome, the American Heart Association (AHA) has published key recommendations from an international panel discussion that took place on May 2, 2020.
- The Pediatric Intensive Care-COVID-19 International Collaborative presented the panel, which included representatives from the AHA’s Young Hearts Council, among others.
Why this matters
- Most children with COVID-19 will be asymptomatic or have a mild disease course, the AHA said in a news release.
- Since March, however, reports have emerged of a rare, Kawasaki-like presentation in a relatively small number of children, with some deaths.
- Kawasaki can lead to heart damage and to coronary artery damage that can persist.
Key points
- Case definition: presentation includes persistent fever, inflammation (per cell counts, sequential biomarkers, cytokine panels, antibody testing where available), organ dysfunction.
- Exclude other microbial causes.
- SARS-CoV-2 testing has been negative in some cases, despite confirmed exposure.
- Patients will require multidisciplinary care, including from cardiology and infectious disease specialists.
- Serial echocardiography of coronary arteries is recommended; arteries may be enlarged.
- Tertiary centers or cardiac ICUs are necessary for care because of potential for rapid deterioration.
- Enroll children where applicable in research protocols associated with biobanking.
- Follow carefully all children with unexplained fever, elevated C-reactive protein/white blood cell count to monitor for progression or sudden worsening, even in apparently mild cases.
Dieser Volltext ist leider reserviert für Angehöriger medizinischer Fachkreise
Sie haben die Maximalzahl an Artikeln für unregistrierte besucher erreicht
Kostenfreier Zugang Nur für Angehörige medizinischer Fachkreise